VivoSim CCO buys 10,000 shares at $0.28

Rhea-AI Filing Summary

VivoSim Labs, INC. (VIVS) reported that its Chief Commercial Officer, Lialin Tony Serge, purchased 10,000 shares of common stock on 2026-08-31 at an average price of $0.2804 per share in an open-market or private transaction. Following this trade, he held 10,000 shares directly, and the filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Lialin Tony Serge

Role Chief Commercial Officer

Bought 10,000 shs ($3K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$0.2804	$3K

Holdings After Transaction: Common Stock — 10,000 shares (Direct)

Key Figures

Shares purchased: 10,000 shares of Common Stock Purchase price per share: $0.2804 per share Approximate transaction value: $2,804 +1 more

4 metrics

Shares purchased 10,000 shares of Common Stock Non-derivative open-market or private purchase on 2026-08-31

Purchase price per share $0.2804 per share Price for the 10,000-share purchase on 2026-08-31

Approximate transaction value $2,804 10,000 shares purchased at $0.2804 per share

Shares owned after transaction 10,000 shares Direct ownership by Lialin Tony Serge following the reported trade

Key Terms

Rule 10b5-1, open market or private transaction, direct ownership

3 terms

Rule 10b5-1 regulatory

"the filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open market or private transaction financial

"Purchase in open market or private transaction"

direct ownership financial

"directly owns 10,000 shares following the transaction"

FAQ

What insider transaction did VIVS report for Lialin Tony Serge?

VivoSim Labs, INC. reported that Chief Commercial Officer Lialin Tony Serge purchased 10,000 shares of VIVS common stock on 2026-08-31 in an open-market or private transaction at an average price of $0.2804 per share.

How many VIVS shares does Lialin Tony Serge own after this Form 4 transaction?

After the reported purchase, Chief Commercial Officer Lialin Tony Serge directly owns 10,000 shares of VivoSim Labs, INC. common stock, as stated in the filing’s post-transaction ownership figure.

Was the VIVS insider trade by Lialin Tony Serge under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as being under a trading plan, indicating the reported purchase of 10,000 VIVS shares was not affirmed as made pursuant to a Rule 10b5-1 trading arrangement.

What price did Lialin Tony Serge pay per VIVS share in the reported transaction?

He paid an average price of $0.2804 per share for the 10,000 VIVS common shares purchased on 2026-08-31, according to the transaction price field, which is identified as a per-share amount.

What is the approximate total dollar value of the VIVS shares Lialin Tony Serge purchased?

The purchase of 10,000 shares at $0.2804 per share represents an approximate total transaction value of $2,804, based on multiplying the reported share count by the reported per-share price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:02 PM Accepted by SEC EDGAR 09/01/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lialin Tony Serge

(Last) (First) (Middle)

11555 SORRENTO VALLEY ROAD

SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VivoSim Labs, INC. [ VIVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		P		10,000	A	$0.2804	10,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Norman Staskey, attorney-in-fact	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)